JNJ Set for Q3 Earnings: Multiple Myeloma Portfolio Shines
Johnson & Johnson is set to report its third-quarter results on October 13. The company's second-quarter revenue grew 6.6% year-over-year to $25.31 billion, primarily due to strong performance in the multiple myeloma portfolio and Tremfya.
In a recent update, Johnson & Johnson said that modeling projects nearly fourfold longer median overall survival with Tecvayli+Darzalex Faspro versus SoC in patients with R/R multiple myeloma. This is significant news for investors who are watching the company's progress in this area.
Despite trading at a premium, with a P/E ratio of 24.5x that is 30.4% higher than the sector median and 45% higher than its 5-year average, Johnson & Johnson has several strengths that make its risk/reward profile balanced. Analysts will be watching to see how these factors impact the company's third-quarter results.